WELD is a fitness company on a mission to make on-demand health, fitness and wellbeing available to all ages & abilities. The company allows users and instructors to set the time and place for the training session, rent out their home or commercial spaces for activities, or interact 1-2-1 online. This approach, the company believes, helps personal trainers, hit by the Covid-19 lockdown, find clients. WELD also allows trainers to set their prices and keep 90% of their fees, and lets customers enjoy a 2% commission on referrals for every future session taken in perpetuity. WELD aims to tap into the $94 billion global fitness and wellness market that grew 8.7% from 2018/19. The company's primary target audience is Generation Z that, the company believes, embraced wellness. WELD will use the investment to improve its platform, boost marketing and plug the fitness & wellness gap.
days to go:
Expired
investment:
£199,227
Scribestar's Software-as-a-Service (SaaS) platform digitises and automates the documentation and compliance processes required for raising capital on stock markets such as IPOs, bonds etc. The platform intends to provide users with structured data format documents that can be machine-read and monetised. Scribestar aims to become a contender in the $22 billion Regulatory/Legal Technology markets. It argues that it is already active in the UK and has witnessed over 50 transactions on its system. It is also a part of the London Stock Exchange Issuer Services and CMS equIP with 4 years of verifiable commercial use and over £13 million received as investments. Scribestar asserts that its services are being regularly used by three law firms in the UK with more showing interest in its capability to function as a remote tool to manage the compliance documentation process. The company will use the investment to start its expansion in the US and other markets targeting law firms and deliver successful trials with stock exchanges.
days to go:
Expired
investment:
£864,009
Crosspay is a company that aims to make remittance simpler and cheaper. The company built its proprietary system in 2017 to bolster international transfers at a fraction of the money charged by traditional Over-The-Counter (OTC) services. It has since powered over 50,000 transactions across 50 countries with a cumulative value of approx £32,350,000. The company aspires to become the segment leader in the more than $200 billion global remittance market. Crosspay was rated 'Excellent' on Trustpilot. It also created white-labelled apps for charities and churches to host content, broadcast live and receive donations simultaneously, irrespective of location. The company has been invited to partner on an Innovate UK project. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£212,581
Personalised Co. is a nutrition company on a mission to help as many people as possible reach their health and wellbeing goals by making supplements accessible and affordable. The company asserts that it provides personalised nutritional products to its consumers. Customers are required to take a quiz on the company's portal, based on which, the company's custom-built algorithm creates nutritionist-approved solutions tailored to the specific needs and goals of each customer. Personalised Co. has delivered 270,000 daily vitamin sachets till date. The company has also raised £192,000 from private investors and its first crowdfunding campaign in 2019. It achieved its milestone month in April 2020 earning £48,000 in revenue and delivering over 1,700 personalised vitamins and protein orders. The company will use the investment to level-up its operations, expand its product line and develop its companion-application.
days to go:
Expired
investment:
£401,417
Spotlight Consultations aims to diagnose diseases based on evidence-based questionnaires. The company's Algorithmic Questionnaire (AQ) strives to be a simple 3-5 minute questionnaire, dynamically responsive with each question linked to an actionable care pathway. The company estimates that 10% of global health expenditure per annum is spent on diabetes, which is predicted to rise to $825 billion by 2030. Indirect costs from premature death, disability, and diabetes-related health complications add an additional 35% more to this number. Spotlight intends for its AQ to help reduce expenditure and healthcare burden while improving the quality of care and health outcomes. The company will use the investment to support early revenue generation, team expansion and stimulate Research and Development (R&D) tools to cover more diseases like CVD, IBD, chronic pain, and cancers.
days to go:
Expired
investment:
£69,682
Moody is a health-tracking application that connects users with customised health, food and fitness advice based on their moods, symptoms and cycles. It endeavours to become a sustainable force for good in women's health. The company argues that women control >80% of household health spend and are 80% more likely than men to use a digital health app. It aims to harness these trends and capitalise on the global remote health care market that is forecast to hit £40 billion by 2025. 'The Moody Month' app featured in publications like Vogue, Grazia and The Guardian. It has witnessed over 136,000 downloads since its Version 1 release in 2019. The app has compiled over 5 million moods to date. The company will use the investment to scale its business globally and reach 1 million subscribers within a four-year time frame.
days to go:
Expired
investment:
£142,026
Sendit.Money is a remittance entity. It argues that individuals sending or receiving money in emerging markets can face insecure processes, slow transaction times and incur high costs. Sendit.Money asserts that this is because non-fiat currencies are changed multiple times before they are received. The company aims to change this. Its prototype application for African markets was received amidst positive feedback. It is now building a cost-effective mobile wallet providing a secure and inexpensive way to send and receive money that also allows users to compare transfer fees of different remittance agents in real-time. Sendit.Money was shortlisted as Best Global start-up at the 2020 Wales Startup Awards. The company will build and launch its Most Valuable Product (MVP) in Q3 of 2021. It will also use the funding to begin work with an authorised entity to become an approved representative.
days to go:
Expired
investment:
£182,732
Wirex is a UK financial technology company that aims to bring crypto & fiat currencies together on one simple payments portal. The company is building a platform where buying, holding, saving and spending any digital and traditional currency is quick, easy and accessible. The Wirex app supports 12 fiat and 10 crypto currencies, operates in 130 countries, and has more than 3.1 million registered users. Wirex launched the first Visa crypto-enabled payments card in the world. It has a £3 billion cumulative transaction volume and plans to expand to the USA by end-2020. Wirex will use the investment to allow millions of its users to own a share of the brand.
days to go:
Expired
investment:
£3,703,120
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
